Repligen Corporation (RGEN): Price and Financial Metrics

Repligen Corporation (RGEN)

Today's Latest Price: $176.25 USD

0.00 (0.00%)

Updated Oct 26 9:36am

Add RGEN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

RGEN Stock Summary

  • With a one year PEG ratio of 2,928.9, Repligen Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 98.59% of US stocks.
  • RGEN's current price/earnings ratio is 291.47, which is higher than 97.47% of US stocks with positive earnings.
  • The price/operating cash flow metric for Repligen Corp is higher than 97.26% of stocks in our set with a positive cash flow.
  • Stocks that are quantitatively similar to RGEN, based on their financial statements, market capitalization, and price volatility, are TDOC, MLAB, PRAH, PAYC, and AKAM.
  • Visit RGEN's SEC page to see the company's official filings. To visit the company's web site, go to

RGEN Stock Price Chart Interactive Chart >

Price chart for RGEN

RGEN Price/Volume Stats

Current price $176.25 52-week high $177.92
Prev. close $176.25 52-week low $76.85
Day low $174.95 Volume 5,689
Day high $176.27 Avg. volume 518,889
50-day MA $154.92 Dividend yield N/A
200-day MA $124.50 Market Cap 9.25B

Repligen Corporation (RGEN) Company Bio

Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.

RGEN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$176.25$18.31 -90%

We started the process of determining a valid price forecast for Repligen Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Repligen Corp ranked in the 12th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Repligen Corp, consider:

  • In the past 5.38 years, Repligen Corp has a compound free cash flow growth rate of 0.25%; that's higher than 61.59% of free cash flow generating stocks in the Healthcare sector.
  • 97% of the company's capital comes from equity, which is greater than 89.36% of stocks in our cash flow based forecasting set.
  • The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 10.6% of US stocks with free cash flow have a lower reliance on debt in their capital structure.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Repligen Corp? See BLFS, LGND, VAR, ELAN, and PCRX.

RGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

RGEN Latest Social Stream

Loading social stream, please wait...

View Full RGEN Social Stream

Latest RGEN News From Around the Web

Below are the latest news stories about Repligen Corp that investors may wish to consider to help them evaluate RGEN as an investment opportunity.

Repligen Corporation's (RGEN) CEO Tony Hunt on Q2 2020 Results - Earnings Call Transcript

Repligen Corporation (RGEN) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Financial Corp. Puneet Souda -...

SA Transcripts on Seeking Alpha | July 31, 2020

Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?

Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Yahoo | July 31, 2020

Repligen Gaps Up On Earnings

Repligen's bioprocessing products are helping customers fast-track Coronavirus vaccines and therapies.

Yahoo | July 30, 2020

Repligen (RGEN) Q2 Earnings and Revenues Top Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 50.00% and 11.98%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2020

Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance

* Reports record quarterly revenue of $87.5 million * Overall revenue grew 24% year-over-year, with organic growth of 19% * Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth * Completes acquisition of silicone molding and tubing manufacturer Engineered Molding TechnologyWALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call.Tony J. H...

Yahoo | July 30, 2020

Read More 'RGEN' Stories Here

RGEN Price Returns

1-mo 22.14%
3-mo 28.58%
6-mo 50.98%
1-year 122.65%
3-year 362.36%
5-year 412.35%
YTD 90.54%
2019 75.39%
2018 45.37%
2017 17.72%
2016 8.94%
2015 42.88%

Continue Researching RGEN

Want to see what other sources are saying about Repligen Corp's financials and stock price? Try the links below:

Repligen Corp (RGEN) Stock Price | Nasdaq
Repligen Corp (RGEN) Stock Quote, History and News - Yahoo Finance
Repligen Corp (RGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8029 seconds.